Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer - LARVOL DELTA

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia (clinicaltrials.gov) - P=N/A | N=846279 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness of Infant Pneumococcal Conjugate Vaccination Strategies in Vietnam: A Stepwise Economic Evaluation. (PubMed, Vaccines (Basel)) - " Vaccinating infants in Vietnam through the private market or an NIP with PCV13 or PCV20 was estimated to be more cost-effective or cost saving than strategies based on PCV10 or PCV15, respectively. These findings provide valuable evidence to inform policy decisions."

HEOR • Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia

IS04 - From immunogenicity to public health impact: the first real-world evidence of PCV20 performance against clinical outcomes in adults (ESCMID Global 2026) - "Vaccination with PCV20 can help reduce this burden by providing broad protection against 20 of the key pneumococcal serotypes that have been associated with clinical characteristics such as disease severity and antimicrobial resistance. Join us to learn about the first real-world evidence of PCV20 effectiveness and associated public health impact in older adults."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Infectious Disease • Pneumococcal Infections

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months (clinicaltrials.gov) - P=N/A | N=1100 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Mar 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2027 ➔ Dec 2026

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Jun 2026 ➔ Oct 2026 | Trial primary completion date: Jun 2026 ➔ Oct 2026

Real-world evidence • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study to Learn About How a New Pneumococcal Vaccine Works in Children (clinicaltrials.gov) - P2 | N=225 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan (clinicaltrialsregister.eu) - P3 | N=540 | Sponsor: Pfizer Inc.

New P3 trial • Dermatology • Infectious Disease • Pneumococcal Infections • Pneumonia

PCV20 FOR HIGH-RISK POPULATIONS: A COST-UTILITY ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE (ISPOR 2026) - "These results support the use of PCV20 as a simplified and cost-effective strategy for preventing PD in vulnerable people, supporting its inclusion into the NIP."

Clinical • HEOR • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

4304 - The Pneumovax 23 Vaccine is Going Away: What Now: Update on Tools for Diagnosing Immunodeficiencies (AAAAI 2026) - "The landscape of pneumococcal vaccines is shifting, with the phase-out of Pneumovax 23 and increasing use of Prevnar 20/21. This session will also prepare you to recognize these diseases and prepare your practice for the risks and complications associated with these infections. Learning Objectives: - Explain guidelines on diagnostic vaccination in the evaluation of immunodeficiency- Describe how immunomodulatory medications affect vaccine response- Discuss vaccine preventable diseases in the era of declining herd immunity CME: 1.25 CE: 1.25 Participation: 1.25"

Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency

A Study of V118E in Healthy Participants (V118E-003) (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: May 2027 ➔ Nov 2027 | Trial primary completion date: May 2027 ➔ Nov 2027

Trial completion date • Trial primary completion date

A Multi-Country Comparison of Number Needed to Vaccinate for PCV20 and PCV15 in Infants. (PubMed, Vaccines (Basel)) - "To achieve the same disease reduction as PCV20, over five times as many children would need to be vaccinated with PCV15. These findings suggest PCV20 may offer greater public health impact compared with PCV15 in infant immunization programs."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13. (PubMed, Vaccine) - "Pediatric PCV20 use is projected to reduce pneumococcal disease burden and healthcare costs in the US compared with PCV15 or PCV13. Results support the health and economic value of adopting a higher-valent pediatric vaccination approach using PCV20."

Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (clinicaltrials.gov) - P1 | N=400 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (clinicaltrials.gov) - P1 | N=200 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Incidence of all-cause and vaccine-preventable, radiologically confirmed community-acquired pneumonia in hospitalised adults in Germany: a multicentre surveillance study (2021-2023). (PubMed, BMJ Open) - "Active pneumonia surveillance reported a high burden of RAD-CAP hospitalisations in Germany, especially among older adults. The resurgence of CAP due to RSV, S. pneumoniae or influenza, alongside maintained activity of SARS-CoV-2, was associated with an overall increase of RAD-CAP among adults."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1714 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Utah | Trial completion date: Jan 2028 ➔ Jun 2028 | Trial primary completion date: Jan 2026 ➔ Jun 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults. (PubMed, Hum Vaccin Immunother) - "Immunobridging of PCV20 responses to adults 60-64 y of age supports PCV20 use in adults 18 through 59 y of age, including those at increased risk of pneumococcal disease. Additionally, PCV20 elicited functional responses to all 20 vaccine serotypes in adults ≥65 y old who were previously vaccinated with PCV13 and/or PPSV23."

Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia

CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov) - P3 | N=2226 | Terminated | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Terminated; Sponsor decision

Trial termination • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Hematological Disorders • Infectious Disease • Pneumococcal Infections • Sickle Cell Disease

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials. (PubMed, Vaccine) - P2 | "Multiple formulations of IVT PCV-25, a vaccine designed to cover pneumococcal serotypes prevalent in LMICs, were well tolerated and immunogenic in healthy adults. As adult immunogenicity is not fully predictive for infants, further development will evaluate safety and immunogenicity in the target infant population."

Clinical • Journal • Infectious Disease • Pneumococcal Infections

Cost-effectiveness analysis of a 20-valent pneumococcal conjugate vaccine for pneumococcal disease prevention in the Slovak pediatric population. (PubMed, J Med Econ) - "Direct and indirect vaccine effects (VE) were estimated from vaccine impact, effectiveness, and clinical studies of PCV7 and PCV13...Implementing PCV20 into the Slovakian pediatric NIP is projected to yield the most significant clinical and economic benefits compared to the two lower-valent PCVs, due to its more extensive protection against a broader range of pneumococcal serotypes. Despite an additional cost of dose and visit, PCV20 was estimated to be cost-effective at the Slovak WTP threshold versus other SoC options over a 10-year time horizon."

HEOR • Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion